Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of Predicted INR Control for Stroke Prevention in Atrial Fibrillation
Clinical Trials Saturday, May 11th, 2013CIRCULATIONAHA: May 2, 2013
Background—In the ARISTOTLE trial apixaban compared with warfarin, reduced stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effects in relation to two predictions of time in therapeutic range (TTR).
Methods and Results—The trial randomized 18,201 patients with atrial fibrillation to apixaban 5 mg twice daily or warfarin for at least 12 months. Read more
